Response of ATL patients to AZT-based therapy correlates with theirp53transcriptional status. (A) Immunohistochemistry detection of p53 expression in ATL samples collected from AZT responder (top) and nonresponders (bottom) performed as previously described.³  (B) p53 from ATL patients was cloned into pCDNA3.1 and tested in a functional assay. Jurkat T cells were transfected with a p53-responsive vector and p53 expression vectors and luciferase activity detected 24 hours later. Results are representative of 2 independent experiments.